Tanaka M - Search Results

1

Different roles of tumor marker monitoring after curative resections of gastric and colorectal cancers.

Ohtsuka T, Nakafusa Y, Sato S, Kitajima Y, Tanaka M, Miyazaki K. Ohtsuka T, et al. Among authors: tanaka m. Dig Dis Sci. 2008 Jun;53(6):1537-43. doi: 10.1007/s10620-007-0046-4. Dig Dis Sci. 2008. PMID: 17932750

2

Comparison of multivisceral resection and standard operation for locally advanced colorectal cancer: analysis of prognostic factors for short-term and long-term outcome.

Nakafusa Y, Tanaka T, Tanaka M, Kitajima Y, Sato S, Miyazaki K. Nakafusa Y, et al. Among authors: tanaka m, tanaka t. Dis Colon Rectum. 2004 Dec;47(12):2055-63. doi: 10.1007/s10350-004-0716-7. Dis Colon Rectum. 2004. PMID: 15657654

3

False-positive findings for tumor markers after curative gastrectomy for gastric cancer.

Ohtsuka T, Sato S, Kitajima Y, Tanaka M, Nakafusa Y, Miyazaki K. Ohtsuka T, et al. Among authors: tanaka m. Dig Dis Sci. 2008 Jan;53(1):73-9. doi: 10.1007/s10620-007-9825-1. Epub 2007 May 3. Dig Dis Sci. 2008. PMID: 17476595

4

Loss of expression of DNA repair enzymes MGMT, hMLH1, and hMSH2 during tumor progression in gastric cancer.

Kitajima Y, Miyazaki K, Matsukura S, Tanaka M, Sekiguchi M. Kitajima Y, et al. Among authors: tanaka m. Gastric Cancer. 2003;6(2):86-95. doi: 10.1007/s10120-003-0213-z. Gastric Cancer. 2003. PMID: 12861399

5

Iliac lymph node metastasis of an unknown primary tumor: report of a case.

Matsuyama S, Nakafusa Y, Tanaka M, Yoda Y, Mori D, Miyazaki K. Matsuyama S, et al. Among authors: tanaka m. Surg Today. 2006;36(7):655-8. doi: 10.1007/s00595-006-3211-z. Surg Today. 2006. PMID: 16794805

6

Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: a pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases in gastric cancer tissue specimens.

Kai K, Kitajima Y, Hiraki M, Satoh S, Tanaka M, Nakafusa Y, Tokunaga O, Miyazaki K. Kai K, et al. Among authors: tanaka m. Cancer Lett. 2007 Dec 8;258(1):45-54. doi: 10.1016/j.canlet.2007.08.008. Epub 2007 Sep 24. Cancer Lett. 2007. PMID: 17892912

7

Aberrant methylation of p16 predicts candidates for 5-fluorouracil-based adjuvant therapy in gastric cancer patients.

Mitsuno M, Kitajima Y, Ide T, Ohtaka K, Tanaka M, Satoh S, Miyazaki K. Mitsuno M, et al. Among authors: tanaka m. J Gastroenterol. 2007 Nov;42(11):866-73. doi: 10.1007/s00535-007-2113-1. Epub 2007 Nov 22. J Gastroenterol. 2007. PMID: 18008030 Clinical Trial.

8

Helicobacter pylori infection is an independent risk factor for Runx3 methylation in gastric cancer.

Kitajima Y, Ohtaka K, Mitsuno M, Tanaka M, Sato S, Nakafusa Y, Miyazaki K. Kitajima Y, et al. Among authors: tanaka m. Oncol Rep. 2008 Jan;19(1):197-202. Oncol Rep. 2008. PMID: 18097595

9

[Complete response obtained with first-line therapy as S-1, followed by second-line 5'-DFUR plus paclitaxel therapy in a patient with multiple liver and lymph node metastases from gastric cancer].

Kitajima Y, Yakabe T, Ohtsuka T, Tanaka M, Sato S, Nakafusa Y, Miyazaki K. Kitajima Y, et al. Among authors: tanaka m. Gan To Kagaku Ryoho. 2009 May;36(5):851-4. Gan To Kagaku Ryoho. 2009. PMID: 19461193 Japanese.

10

Phase I/II study of combination therapy with S-1 and CPT-11 for metastatic colorectal cancer.

Nakafusa Y, Tanaka M, Ohtsuka T, Miyoshi A, Kohya N, Kitajima Y, Sato S, Mochinaga S, Dohi S, Miyazaki K. Nakafusa Y, et al. Among authors: tanaka m. Mol Med Rep. 2008 Nov-Dec;1(6):925-30. doi: 10.3892/mmr_00000051. Mol Med Rep. 2008. PMID: 21479507

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15,439 results

Search Page

Filters